Table 2. . Performance of single metabolite models versus model for end-stage liver disease-Na score predicting 1-year mortality in 39 patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis.
| Plasma metabolites | Hazard ratio† | p-value for hazard ratio | Time-dependent AUROC (at 1 year)‡ | AUROC 95% confidence limits (lower)§ | AUROC 95% confidence limits (upper)§ |
|---|---|---|---|---|---|
| Myo-inositol | 4.967 | 0.0013 | 0.9537 | 0.5612 | 1.0000 |
| N-Acetylputrescine | 3.343 | 0.0052 | 0.9018 | 0.7763 | 1.0000 |
| Trans-aconitate | 2.080 | 0.0181 | 0.8880 | 0.7149 | 1.0000 |
| N-Acetylalanine | 0.040 | 0.0009 | 0.8438 | 0.1627 | 1.0000 |
| Erythronate | 7.595 | 0.0010 | 0.8345 | 0.7094 | 0.9595 |
| N1-Methyladenosine | 13.113 | 0.0038 | 0.8279 | 0.3914 | 1.0000 |
| N6-Carbamoylthreonyladenosine | 13.420 | 0.0002 | 0.8055 | 0.5991 | 1.0000 |
| N2,N2-Dimethylguanosine | 27.828 | 0.0003 | 0.8055 | 0.5816 | 1.0000 |
| Pseudouridine | 0.732 | 0.6581 | 0.7837 | 0.2180 | 1.0000 |
| Glucuronate | 4.590 | 0.0004 | 0.7828 | 0.5997 | 0.9659 |
| Dimethylarginine (SDMA + ADMA) | 5.255 | 0.0087 | 0.7790 | 0.5566 | 1.0000 |
| N4-Acetylcytidine | 0.759 | 0.1244 | 0.7716 | 0.5108 | 1.0000 |
| MELD-Na score | 1.162 | 0.0020 | 0.7591 | 0.5553 | 0.9628 |
| Picolinate | 2.628 | 0.1060 | 0.7510 | 0.5272 | 0.9748 |
| Creatinine | 3.741 | 0.0605 | 0.7449 | 0.1407 | 1.0000 |
| 3-(4-Hydroxyphenyl)lactate | 2.951 | 0.0056 | 0.7288 | 0.4799 | 0.9777 |
| 3-Methoxtyrosine | 0.139 | 0.0066 | 0.7248 | 0.3760 | 1.0000 |
| Xylitol | 4.130 | 0.1032 | 0.7151 | 0.1167 | 1.0000 |
| Cystathionine | 1.972 | 0.0143 | 0.7150 | 0.4541 | 0.9759 |
| 1-Methylhistidine | 1.967 | 0.0097 | 0.6893 | 0.4248 | 0.9537 |
| Cytidine | 2.516 | 0.0690 | 0.6867 | 0.2664 | 1.0000 |
| 4-Acetamidobutanoate | 2.547 | 0.0007 | 0.6649 | 0.4267 | 0.9032 |
| Gamma-glutamylphenylalanine | 0.569 | 0.5629 | 0.6626 | 0.1644 | 1.0000 |
| N-Formylmethionine | 3.838 | 0.0851 | 0.6591 | 0.2915 | 1.0000 |
| N-Acetylserine | 1.185 | 0.5744 | 0.6462 | 0.3149 | 0.9775 |
| S-Adenosylhomocysteine | 2.132 | 0.4237 | 0.6205 | 0.0874 | 1.0000 |
| Adenosine | 0.800 | 0.1537 | 0.5857 | 0.2650 | 0.9064 |
| Phenyllactate | 5.234 | 0.0998 | 0.5775 | 0.0838 | 1.0000 |
| Adenine | 1.252 | 0.3103 | 0.5713 | 0.1576 | 0.9849 |
| N6-Acetyllysine | 1.271 | 0.6092 | 0.5489 | 0.3094 | 0.7884 |
| 7-Methylguanine | 2.535 | 0.3854 | 0.5290 | 0.0823 | 0.9757 |
| 3-Methoxytyramine Sulfate | 1.425 | 0.5396 | 0.5109 | 0.1052 | 0.9167 |
| N-Acetylvaline | 0.803 | 0.4900 | 0.4993 | 0.1065 | 0.8922 |
| 3-Ureidopropionate | 0.867 | 0.8197 | 0.4098 | 0.0000 | 0.8829 |
Bold font highlights the MELD-Na score.
Metabolites were expressed on a log2 scale – hazard ratios represent the risk of death associated with one log2 unit increment.
Data were sorted by AUROC (largest to smallest), then by p-value (smallest to largest).
CIs that did not include 0.50 were considered significant (e.g. 95% CIs for the AUROC of myo-inositol model is significant because it did not include 0.50). Several plasma metabolites predicted 1-year mortality with significantly greater accuracy (AUROC) compared with the accuracy (AUROC) of the MELD-Na score.
SDMA; ADMA.
ADMA: Asymmetric dimethylarginine; AUROC: Area under the receiver operating characteristic curve; MELD-Na: Model for end-stage liver disease-Na; SDMA: Symmetric dimethylarginine.